Eli Lilly Licenses Camurus' FluidCrystal Technology for Cardiometabolic Drugs

Eli Lilly has licensed Camurus' FluidCrystal technology for its cardiometabolic drugs. The technology allows for the sustained release of drugs, potentially improving their efficacy and convenience. The deal is significant for Lilly, which is one of the world's leading pharmaceutical groups with a focus on endocrinology, oncology, immunology, neurology, and other fields. The technology has the potential to enhance Lilly's offerings in the cardiometabolic space.